Ready 8-Ks
13
Latest filing
May 18, 2026 20:15 UTC
Top materiality
0.85
Event mix
other_material ×6 · earnings ×4 · leadership ×1
Sentiment
4 pos · 0 neg · 9 neu
Latest earnings
reported 2026-Q1
-
May 14, 2026 11:20 UTC
earnings
materiality 0.85
positive
item 2.02item 9.01
Cellectar reports Q1 net loss $5.7M; positive iopofosine data, up to $140M financing
Q1 net loss $5.7M ($1.33/share) vs $6.6M ($4.30/share) YoY; cash $8.3M at March 31.
-
May 08, 2026 23:59 UTC
other_material
materiality 0.80
positive
item 1.01item 3.02item 8.01item 9.01
Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data
Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.
-
Mar 04, 2026 23:59 UTC
earnings
materiality 0.60
neutral
item 2.02item 9.01
Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026
Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.
-
Nov 13, 2025 23:59 UTC
earnings
materiality 0.60
neutral
item 2.02item 9.01
Cellectar Q3 net loss $4.4M ($1.41/sh); cash $12.6M; progress on EU conditional marketing for iopofosine
Net loss narrowed to $4.4M ($1.41/sh) from $14.7M ($11.18/sh) YoY; R&D spending fell to $2.5M.
-
Oct 10, 2025 23:59 UTC
other_material
materiality 0.75
positive
item 1.01item 2.02item 3.02item 3.03item 8.01item 9.01
Cellectar raises ~$5.8M via warrant exercise; prelim cash $12.6M as of Sep 30
Gross proceeds of ~$5.8M from exercise of 1,048,094 existing warrants at $5.25/share; holders paid $0.125 per new warrant.
-
Oct 06, 2025 23:59 UTC
regulatory
materiality 0.75
positive
item 7.01item 8.01item 9.01
EMA confirms iopofosine I 131 eligible for Conditional Marketing Authorization in post-BTKi WM
SAWP advised filing a CMA for iopofosine I 131 in post-BTKi refractory WM could be acceptable.
-
Aug 14, 2025 23:59 UTC
earnings
materiality 0.70
neutral
item 2.02item 9.01
Cellectar to pursue accelerated NDA for iopofosine I 131 in WM; Q2 net loss $5.4M
Plans NDA submission for accelerated approval of iopofosine I 131 in WM, subject to sufficient funding and confirmatory trial initiation.
-
Jun 26, 2025 23:59 UTC
other_material
materiality 0.65
neutral
item 8.01
Cellectar provides clinical updates, plans Phase 1 studies for CLR 125 and CLR 225 in H2 2025 subject to financing
CLR 125 (Auger-emitting PRC) Phase 1b study in triple-negative breast cancer planned for H2 2025, subject to additional financing.